ArticleBMC veterinary research2025
Long-term efficacy of cyclosporine and interferon-ω in feline chronic gingivostomatitis: insights from SDAI scores.
Article in BMC veterinary research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundFeline chronic gingivostomatitis (FCGS) is a challenging disease with unclear causes and limited treatment options. The most effective treatment for FCGS is tooth extraction. However, most cats require additional drug treatment for refractory FCGS even after undergoing extractions. We hypothesized that the combination of interferon-ω (IFN) and cyclosporine (CsA) would improve clinical outcomes. This study aimed to evaluate the long-term efficacy of IFN and CsA in FCGS using Stomatitis Disease Activity Index (SDAI) scores. In this study, the treatment process was divided into two stages: in the surgical stage (Stage 1), all cats underwent tooth extraction combined with submucosal IFN injection; in the immunomodulatory stage (Stage 2), additional IFN/CsA treatment was administered to cats with refractory FCGS.
resultsThe therapeutic response was monitored during treatment period using SDAI scores. The patients were classified into four groups by oral examination: Group A (Surgical remission), Group B (Substantial improvement to resolution), Group C (Partial improvement), and Group D (No response). Patients achieving complete remission following surgical treatment were classified into Group A (39.2% of all cases). Patients assessed as having refractory FCGS after surgical treatment accounted for 60.8% of all patients and were divided into three groups. Groups B, C, and D accounted for 52.1%, 45.2%, and 2.7% of refractory cases, respectively. In addition, the SDAI scores showed significant differences across groups at all time points. Receiver operating characteristic curve analyses identified key SDAI thresholds for early classification: a T
conclusionThis study showed that the combination of IFN and CsA is an effective therapeutic option for refractory FCGS, with more than half of treated cats showing clinical improvement and 76.5% of those achieving subs-resolution at 6 months maintaining remission for 2-6 years. These findings further indicate that evaluating SDAI scores six months after a three-month course of immunomodulatory therapy provides prognostic value for predicting long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.